Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01536015 · ClinicalTrials.gov registry record · Phase 3
Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction
A Phase 3 study, sponsored by UCB Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
NCT01536015 is a Phase 3 study that was terminated before completion, run by UCB Pharma. The registered enrollment target is 25 participants.
The verdict
NCT01536015, a Phase 3 study, was terminated before completion, sponsored by UCB Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
Study Summary
The primary purpose is to demonstrate superiority of Rotigotine over Placebo on motor symptoms when used in subjects with symptoms of Gastrointestinal Dysfunction. Hypothesis: Rotigotine will decrease OFF time compared to Placebo.
Interventions
- DRUG Placebo
- DRUG Rotigotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01536015
The ClinicalTrials.gov registry entry for NCT01536015 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01536015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01536015 about?
NCT01536015 is a clinical study titled "Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction". The primary purpose is to demonstrate superiority of Rotigotine over Placebo on motor symptoms when used in subjects with symptoms of Gastrointestinal Dysfunction. Hypothesis: Rotigotine will decrease OFF time compared to Placebo.
What is the current status of trial NCT01536015?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2012-01. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01536015?
The interventions under investigation include: Placebo (DRUG), Rotigotine (DRUG).
Who is sponsoring clinical trial NCT01536015?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.